(STE) STERIS - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: IE00BFY8C754
STE: Sterilizers, Cleaning, Chemicals, Equipment, Sterilants, Services
STERIS plc (NYSE:STE) is a global leader in infection prevention, serving as a critical player in maintaining healthcare safety and efficiency. Their operations span three key segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, each tailored to meet specific industry needs.
The Healthcare segment is integral to sterile processing departments, offering a range of products from cleaning chemistries to capital equipment like sterilizers and surgical equipment. Their comprehensive services include installation, maintenance, and repair, ensuring healthcare facilities operate seamlessly. This segment underscores STERISs commitment to reliability and innovation in patient care environments.
The AST segment specializes in contract sterilization and testing services, supported by a network of state-of-the-art facilities. They also provide sterilization equipment to medical device manufacturers and research institutions, highlighting their role in ensuring product safety and compliance in the medical and pharmaceutical sectors.
The Life Sciences segment delivers consumable products and services crucial for cleanroom environments, including high-purity water and steam generators. Their offerings support pharmaceutical manufacturing, emphasizing the importance of contamination control and sterility in research and production settings.
With a market cap of over $21.5 billion, STERIS demonstrates financial stability and investor confidence. While the current P/E ratio reflects its premium valuation, the forward P/E suggests expectations of robust growth. This aligns with global trends towards increased healthcare spending and the demand for infection control solutions, positioning STERIS as a strategic long-term investment in a growing industry.
Investors and fund managers should recognize STERISs role in critical healthcare infrastructure, underpinned by a history of reliability and customer-centric innovation. Their diverse offerings and commitment to quality position them as a resilient player in the healthcare equipment sector.
Additional Sources for STE Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
STE Stock Overview
Market Cap in USD | 22,819m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1992-06-01 |
STE Stock Ratings
Growth 5y | 43.1% |
Fundamental | 52.3% |
Dividend | 56.7% |
Rel. Strength Industry | -3.1 |
Analysts | 3.89/5 |
Fair Price Momentum | 225.26 USD |
Fair Price DCF | 176.72 USD |
STE Dividends
Dividend Yield 12m | 0.74% |
Yield on Cost 5y | 1.27% |
Annual Growth 5y | 7.20% |
Payout Consistency | 96.9% |
STE Growth Ratios
Growth Correlation 3m | 80.6% |
Growth Correlation 12m | -5.8% |
Growth Correlation 5y | 63.2% |
CAGR 5y | 11.81% |
CAGR/Max DD 5y | 0.33 |
Sharpe Ratio 12m | -0.25 |
Alpha | -6.11 |
Beta | 0.03 |
Volatility | 20.20% |
Current Volume | 858.9k |
Average Volume 20d | 427.9k |
As of March 13, 2025, the stock is trading at USD 228.06 with a total of 858,866 shares traded.
Over the past week, the price has changed by +1.00%, over one month by +2.10%, over three months by +8.80% and over the past year by -1.76%.
Partly, yes. Based on ValueRay Fundamental Analyses, STERIS (NYSE:STE) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 52.27 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of STE as of March 2025 is 225.26. This means that STE is currently overvalued and has a potential downside of -1.23%.
STERIS has received a consensus analysts rating of 3.89. Therefor, it is recommend to buy STE.
- Strong Buy: 3
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, STE STERIS will be worth about 243.3 in March 2026. The stock is currently trading at 228.06. This means that the stock has a potential upside of +6.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 250.1 | 9.7% |
Analysts Target Price | 248.3 | 8.9% |
ValueRay Target Price | 243.3 | 6.7% |